Canadian Hemophilia Society -

Title

CHS James Kreppner Memorial Scholarship and Bursary Program
CHS/SCH | 02/12/2020
Information including the criteria and application forms for the CHS James Kreppner Memorial Scholarship and Bursary Program is available on the CHS website at www.hemophilia.ca/james-kreppner-memorial-scholarship-and-bursary-program. The deadline to submit...

European Haemophilia Consortium New Products Review
David Page | 30/11/2020
Read the latest research news about innovative coagulation products – factor replacement products, non-factor therapies and gene therapies – in the European Haemophilia Consortium New Products Review: www.ehc.eu/ehc-npr-2020_vol2 ...

A Patient Videoconference on Inhibitors & New Novel Therapies – Answering Your Questions!
CHS/SCH | 04/11/2020
On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a special focus on emicizumab....

COVID-19 updates
CHS/SCH | 14/10/2020
Access the most updated information regarding COVID-19 and inherited bleeding disorders: www.hemophilia.ca/covid-19

Features
- CHS/SCH | 09/11/2020
  Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
- CHS/SCH | 06/10/2020
  WFH Advisory: availability of desmopressin
- CHS/SCH | 23/09/2020
  Products in the pipeline
- CHS/SCH | 09/09/2020
  Coagulation products
- David Page | 02/09/2020
  WFH publishes 3rd Edition of the Guidelines for the Management of Hemophilia
- David Page | 01/09/2020
  FDA denies approval of Biomarin’s FVIII gene therapy
- Kathy Lawday | 12/08/2020
  Management of comorbidities in bleeding disorders
- Kathy Lawday | 12/08/2020
  Substitution therapy

INNOVATORS

BUILDER

Believers